Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 10/20 | 0.82 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | G6PD | P11413 | 1/20 | 0.57 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.57 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | BTK | Q06187 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3250475 | 1.00 | DHODH (0.82) | DHODHMEN1KMT2AG6PDCACNA1B | |
| SCHEMBL5914902 | 1.00 | DHODH (0.82) | DHODHMEN1KMT2AG6PDCACNA1B | |
| SCHEMBL21067830 | 0.90 | DHODH (1.00) | DHODHMEN1KMT2AG6PDCACNA1B | |
| SCHEMBL12588738 | 0.89 | DHODH (0.67) | DHODHMEN1KMT2AG6PDCACNA1B | |
| SCHEMBL8810371 | 0.88 | DHODH (0.74) | DHODHMEN1KMT2AG6PDCACNA1B | |
| SCHEMBL9079477 | 0.88 | DHODH (0.74) | DHODHMEN1KMT2AG6PDCACNA1B | |
| SCHEMBL9080958 | 0.88 | DHODH (0.74) | DHODHMEN1KMT2AG6PDCACNA1B | |
| SCHEMBL8810121 | 0.88 | DHODH (0.74) | DHODHMEN1KMT2AG6PDCACNA1B | |
| SCHEMBL12202668 | 0.86 | DHODH (0.72) | DHODHMEN1KMT2AG6PDCACNA1B | |
| SCHEMBL7517127 | 0.86 | DHODH (0.68) | DHODHMEN1KMT2AG6PDCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5773470-A | TREATING RHEUMATIC DISEASES, AUTOIMMUNE DISEASES AND REJECTION REACTIONS DUE TO ORGAN TRANSPLANTING | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-06-30 | — | — | US | claimed |
| US-5747664-A | N-Phenyl-2-cyano-3-hydroxycrotonamide derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-05 | — | — | US | claimed |
| EP-0538783-B1 | N-phenyl-2-cyano-3-hydroxycrotonic acid amid derivatives and their use as medicaments having immunomodulating properties | HOECHST AG (DE) | 1995-09-27 | — | — | EP | claimed |
| EP-1606246-B1 | METHOD FOR PRODUCING 2-CYAN-3-HYDROXY-N-(PHENYL)BUT-2-ENE AMIDES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-05-19 | — | — | EP | disclosed |
| CN-100361967-C | Process for the preparation of 2-cyano-3-hydroxy-N- (phenyl) but-2-enamides | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-01-16 | — | — | CN | disclosed |
| CN-100361967-C | Process for the preparation of 2-cyano-3-hydroxy-N- (phenyl) but-2-enamides | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-01-16 | — | — | CN | disclosed |
| US-20060167090-A1 | BTK inhibitors | PARKER HUGHES INSTITUTE (US) | 2006-07-27 | — | — | US | disclosed |
| CN-1756737-A | Process for the preparation of 2-cyano-3-hydroxy-N- (phenyl) but-2-enamides | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-04-05 | — | — | CN | disclosed |
| CN-1756737-A | Process for the preparation of 2-cyano-3-hydroxy-N- (phenyl) but-2-enamides | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-04-05 | — | — | CN | disclosed |
| EP-1606246-A1 | METHOD FOR PRODUCING 2-CYAN-3-HYDROXY-N-(PHENYL)BUT-2-ENE AMIDES | Sanofi-Aventis Deutschland GmbH (DE) | 2005-12-21 | — | — | EP | disclosed |
| EP-1606246-A1 | METHOD FOR PRODUCING 2-CYAN-3-HYDROXY-N-(PHENYL)BUT-2-ENE AMIDES | Sanofi-Aventis Deutschland GmbH (DE) | 2005-12-21 | — | — | EP | disclosed |
| US-6160010-A | BTK inhibitors and methods for their identification and use | PARKER HUGHES INSTITUTE (US) | 2000-12-12 | — | — | US | disclosed |
| WO-1999054286-A2 | BTK INHIBITORS AND METHODS FOR THEIR IDENTIFICATION AND USE | PARKER HUGHES INSTITUTE (US) | 1999-10-28 | — | — | WO | disclosed |
| US-5773470-A | TREATING RHEUMATIC DISEASES, AUTOIMMUNE DISEASES AND REJECTION REACTIONS DUE TO ORGAN TRANSPLANTING | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-06-30 | — | — | US | disclosed |
| US-5773470-A | TREATING RHEUMATIC DISEASES, AUTOIMMUNE DISEASES AND REJECTION REACTIONS DUE TO ORGAN TRANSPLANTING | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-06-30 | — | — | US | disclosed |
| US-5773470-A | TREATING RHEUMATIC DISEASES, AUTOIMMUNE DISEASES AND REJECTION REACTIONS DUE TO ORGAN TRANSPLANTING | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-06-30 | — | — | US | disclosed |
| US-5747664-A | N-Phenyl-2-cyano-3-hydroxycrotonamide derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-05 | — | — | US | disclosed |
| US-5747664-A | N-Phenyl-2-cyano-3-hydroxycrotonamide derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-05 | — | — | US | disclosed |
| US-5747664-A | N-Phenyl-2-cyano-3-hydroxycrotonamide derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-05 | — | — | US | disclosed |
| EP-0538783-A1 | N-phenyl-2-cyano-3-hydroxycrotonic acid amid derivatives and their use as medicaments having immunomodulating properties | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167090-A1 | BTK inhibitors | BTK, SYK, LYN | DHODH 2219/4885MEN1 3599/4885KMT2A 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.